ADAR1 Capital Management LLC Invests $3.74 Million in Xencor, Inc. $XNCR

Key Points

• ADAR1 Capital Management acquired 232,560 Xencor shares worth approximately $3.74 million, representing a 0.31% stake. Several other institutional investors also initiated or increased positions.
• Xencor shares opened at $29.30, near their 52-week high, with the stock up 1.0%. The company reported a quarterly loss of $0.29 per share—better than the $0.80 consensus estimate—and revenue of $51.22 million, up 17.4% year over year.
• Analyst sentiment is mixed but leans positive: five analysts rate Xencor a Buy, three Hold, and one Sell. The consensus rating is Hold, with an average price target of $24.86.

ADAR1 Capital Management LLC acquired a new position in Xencor, Inc. (NASDAQ:XNCR - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 232,560 shares of the biopharmaceutical company's stock, valued at approximately $3,744,000. ADAR1 Capital Management LLC owned 0.31% of Xencor as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Allworth Financial LP acquired a new position in shares of Xencor during the second quarter worth approximately $55,000. Tower Research Capital LLC TRC increased its position in Xencor by 118.4% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 3,018 shares during the period. E Fund Management Co. Ltd. bought a new stake in Xencor during the 2nd quarter valued at $79,000. Norges Bank acquired a new position in Xencor during the 4th quarter worth $175,000. Finally, Prelude Capital Management LLC acquired a new position in Xencor during the 3rd quarter worth $139,000.

Xencor Trading Up 1.0%

XNCR stock opened at $29.30 on Wednesday. Xencor, Inc. has a one year low of $7.71 and a one year high of $30.61. The firm has a market capitalization of $2.18 billion, a PE ratio of -13.50 and a beta of 0.85. The firm has a 50-day moving average of $18.90 and a two-hundred day moving average of $14.45.

Xencor (NASDAQ:XNCR - Get Free Report) last announced its earnings results on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million during the quarter, compared to analysts' expectations of $18.89 million. During the same period last year, the company posted ($0.41) earnings per share. The business's revenue for the quarter was up 17.4% on a year-over-year basis. On average, equities research analysts anticipate that Xencor, Inc. will post -3 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen raised Xencor from a "strong sell" rating to a "hold" rating in a report on Saturday, August 8th. Zacks Research raised Xencor from a "strong sell" rating to a "hold" rating in a report on Monday, July 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a research report on Wednesday, June 24th. Wedbush increased their price target on Xencor from $26.00 to $30.00 and gave the company an "outperform" rating in a research note on Thursday, August 6th. Finally, Truist Financial lowered their price target on Xencor from $29.00 to $27.00 and set a "buy" rating on the stock in a research report on Tuesday, July 7th. Five equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average price target of $24.86.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source